• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- Pixie Dust Technologies/

    10/23/24 4:30:00 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PXDT alert in real time by email

    This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release.

    (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

    NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows:

    1.                  Reasons for Applying for Delisting

    The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets and raise capital through its initial public offering, while benefiting from the increased visibility and credibility of being listed on a major U.S. exchange. Since then, the Company has taken steps to uphold active information disclosure to its shareholders and investors, including the fulfillment of disclosure obligations under the Securities Exchange Act, the preparation of financial statements in accordance with accounting principles generally accepted in the United States, and the establishment of internal control systems as required by the Sarbanes-Oxley Act.

    The Company has now decided to delist its ADRs due to the substantial cost of maintaining its NASDAQ listing and the ongoing reporting obligations of the United States Securities laws, and considering all other facts and circumstances, the Company has decided to divert its financial and human resources toward its business growth. Consequently, the Company has also decided to apply for voluntary delisting from NASDAQ and deregistration from the SEC reporting requirements.

    The Company plans to file Form 25 with the SEC on or about 10 days after Notice to NASDAQ, which will serve as formal notice to the SEC of our intention to delist. The delisting will become effective 10 days after the Form 25 is filed with the SEC.

    2.                  Upon Delisting, the Company's shares will not be listed on any exchange. 

    3.                  Schedule for Delisting and Other Matters (Eastern Standard Time)

    October 23, 2024 (planned)

    Notice of voluntary delisting to NASDAQ;

    Notice regarding termination of deposit

    agreement to depositary bank

    November 4, 2024 (planned)

    Filing of Form 25 with the SEC for delisting

    from NASDAQ and deregistration with the

    SEC

    November 14, 2024 (planned)

    Delisting from NASDAQ to become

    effective

    November 14, 2024 (planned)**

    Filing of Form 15-F with the SEC to

    terminate the Company's ongoing

    disclosure obligations under the Securities

    Exchange Act. Subject to confirmation of

    qualification to file.

    January 21, 2025 (planned)

    Termination of deposit agreement with

    depositary bank to become effective

    (termination of the ADR program)

    February 12, 2025 (planned)**

    Deregistration from SEC to become

    effective, terminating of the Company's

    ongoing disclosure obligations under the

    Securities Exchange Act



    ** subject to 15-F Filing Qualification.

    Note that the schedule above (including planned effective dates) may change if the Company receives notification from the SEC that it objects to deregistration or requests an extended review or for other reasons.

    4.                  After the Delisting and Deregistration

    The Company's ongoing disclosure obligations under the Securities Exchange Act, including the obligation to file annual reports (Form 20-F), will terminate on February 12, 2025, which will be 90 days after the filing of the Form 15-F with the SEC planned November 15, 2024.

    The Company's ADR program is also expected to be terminated on January 21, 2025, in conjunction with the applications for NASDAQ delisting and SEC deregistration. ADR holders with questions should contact The Bank of New York Mellon, the Depositary Bank, using the contact info below.

    After the termination of ADR program, outstanding common shares on deposit with Depositary Bank may be settled in accordance with the Deposit Agreement.

    5.          Forward-Looking Statements

    Certain statements contained in this press release, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning our possible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "believe", "expect", "could", "intend", "plan", "anticipate", "estimate", "continue", "predict", "project", "potential", "target," "goal" or other words that convey the uncertainty of future events or outcomes. You can also identify forward-looking statements by discussions of strategy, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, because forward-looking statements relate to matters that have not yet occurred, they are inherently subject to significant business, competitive, economic, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. These and other important factors, including, among others, those discussed in our most recent annual report for the fiscal year ending April 30, 2024, filed under cover of Form 20-F with U.S. Securities and Exchange Commission, under the headings "Risk Factors", "Operating and Financial Review and Prospects", and "Business Overview" may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements in this annual report. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include our expectations regarding our revenue, expenses, and other operating results.

    6.                  Contact information for inquiries regarding the Company's ADRs:

    Depositary Bank:

    The Bank of New York Mellon (United States)



    Depositary Receipts

    Phone:

    +1 888 269 2377 (USA toll-free number)



    +1 201 680 6825 (International number)



    (Available from Monday through Friday, from 9 a.m. to 5 p.m., Eastern

    Standard Time)

    Website:

    www.adrbny.com

    Mail:

    [email protected]

    For Japanese ADR holders applying for share settlement, the Company established a contact center to provide share settlement guidance. See below.

    Japanese ADR Holders, for ordinary share withdrawal purposes only please contact:

    Company:

    Pixie Dust Technologies delisting call center

    Phone:

    81-3-6636-6314

    Website:

    https://pixiedusttech.com/en/ir

    Mail:

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/amendmentnotice-regarding-plan-to-delist-american-depositary-receipts-from-nasdaq-capital-market-and-deregister-with-us-securities-and-exchange-commission-302286836.html

    SOURCE Pixie Dust Technologies

    Get the next $PXDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What is the new effective date for the delisting from NASDAQ and the Form 15-F filing?

      The effective date for the delisting from NASDAQ is November 14, 2024, and the filing of Form 15-F will also occur on the same date.

    • Why has Pixie Dust Technologies decided to delist from NASDAQ?

      The company decided to delist its ADRs primarily due to the substantial costs of maintaining its NASDAQ listing and the ongoing reporting obligations under U.S. securities laws, opting instead to focus resources on business growth.

    • When will the company's disclosure obligations cease after the delisting?

      Once the delisting and deregistration are complete, the company's ongoing disclosure obligations under the Securities Exchange Act will terminate on February 12, 2025.

    • When will the delisting from NASDAQ officially take effect?

      The delisting will become effective 10 days after the filing of Form 25 with the SEC, which is planned for November 4, 2024.

    • When is the expected termination date for the ADR program?

      The ADR program is expected to be terminated on January 21, 2025, which is in conjunction with the applications for delisting from NASDAQ and deregistration from the SEC.

    Recent Analyst Ratings for
    $PXDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:11:11 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:08:59 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:06:35 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Financials

    Live finance-specific insights

    See more
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024

      NEW YORK and TOKYO, Feb. 11, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Monday, February 12, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/11/24 12:48:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024

      NEW YORK and TOKYO, Feb. 6, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Tuesday, February 13, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/6/24 9:00:00 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    SEC Filings

    See more
    • SEC Form 6-K filed by Pixie Dust Technologies Inc.

      6-K - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/25/24 8:00:20 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Pixie Dust Technologies Inc.

      25 - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/4/24 4:30:02 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.

      6-K/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      10/24/24 1:55:49 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • /C O R R E C T I O N -- Pixie Dust Technologies/

      This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release. (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission. NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Te

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

      NEW YORK and TOKYO, Oct. 23, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows: 1.                  Reasons for Applying for Delisting The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets an

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Pixie Dust Technologies Announces CFO Transition

      NEW YORK and TOKYO, March 13, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, announced the appointment of Nobuhiro Takagi and Nobufusa Tarumi as co-Chief Financial Officer ("co-CFO"), effective March 13, 2024. Messrs. Takagi and Tarumi succeed Mr. Mamoru Miwa, whose resignation was not the result of any disagreement or conflict with the Company, its operations, policies, or practices. The role of the Company's Chief Accounting Officer ("CAO"), previously held by Nobuhiro Takagi, will be assumed by the co-CFOs.

      3/13/24 4:05:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care